25 XP   0   0   10

Pharming Group NV
Buy, Hold or Sell?

Let's analyse Pharming together

PenkeI guess you are interested in Pharming Group NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharming Group NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pharming Group NV

I send you an email if I find something interesting about Pharming Group NV.

Quick analysis of Pharming (30 sec.)










What can you expect buying and holding a share of Pharming? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.31
Expected worth in 1 year
€0.32
How sure are you?
89.7%

+ What do you gain per year?

Total Gains per Share
€0.01
Return On Investment
1.7%

For what price can you sell your share?

Current Price per Share
€0.87
Expected price per share
€0.66 - €0.953
How sure are you?
50%

1. Valuation of Pharming (5 min.)




Live pricePrice per Share (EOD)

€0.87

Intrinsic Value Per Share

€-0.29 - €-0.35

Total Value Per Share

€0.02 - €-0.04

2. Growth of Pharming (5 min.)




Is Pharming growing?

Current yearPrevious yearGrowGrow %
How rich?$218.7m$199.6m$7.4m3.6%

How much money is Pharming making?

Current yearPrevious yearGrowGrow %
Making money-$2.6m$3.4m-$6m-229.6%
Net Profit Margin-6.2%7.2%--

How much money comes from the company's main activities?

3. Financial Health of Pharming (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#224 / 1019

Most Revenue
#141 / 1019

Most Profit
#328 / 1019

Most Efficient
#467 / 1019

What can you expect buying and holding a share of Pharming? (5 min.)

Welcome investor! Pharming's management wants to use your money to grow the business. In return you get a share of Pharming.

What can you expect buying and holding a share of Pharming?

First you should know what it really means to hold a share of Pharming. And how you can make/lose money.

Speculation

The Price per Share of Pharming is €0.868. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharming.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharming, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.31. Based on the TTM, the Book Value Change Per Share is €0.00 per quarter. Based on the YOY, the Book Value Change Per Share is €0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharming.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.00-0.5%0.00-0.5%0.010.6%0.010.8%0.000.1%
Usd Book Value Change Per Share0.010.9%0.000.4%0.011.5%0.011.3%0.011.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.9%0.000.4%0.011.5%0.011.3%0.011.3%
Usd Price Per Share1.10-1.21-0.98-1.09-1.01-
Price to Earnings Ratio-58.83-31.88-14.07--2.62-3.29-
Price-to-Total Gains Ratio145.50-200.82-392.54-248.70-157.93-
Price to Book Ratio3.36-3.87-3.24-5.11-11.86-
Price-to-Total Gains Ratio145.50-200.82-392.54-248.70-157.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.9219028
Number of shares1084
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.01
Usd Total Gains Per Share0.000.01
Gains per Quarter (1084 shares)4.2212.59
Gains per Year (1084 shares)16.8850.37
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1017705040
203424010190
3051410151140
4068580201190
5084750252240
60101920302290
701181090353340
801351260403390
901521430453440
1001691600504490

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%8.04.00.066.7%16.04.00.080.0%20.09.00.069.0%20.09.00.069.0%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%26.03.00.089.7%26.03.00.089.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%26.03.00.089.7%26.03.00.089.7%

Fundamentals of Pharming

About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Fundamental data was last updated by Penke on 2024-04-09 17:01:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Pharming Group NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharming earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • A Net Profit Margin of -3.8% means that €-0.04 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharming Group NV:

  • The MRQ is -3.8%. The company is making a loss. -1
  • The TTM is -6.2%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-3.8%TTM-6.2%+2.4%
TTM-6.2%YOY7.2%-13.4%
TTM-6.2%5Y9.8%-16.0%
5Y9.8%10Y-6.5%+16.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.8%-197.2%+193.4%
TTM-6.2%-210.4%+204.2%
YOY7.2%-279.3%+286.5%
5Y9.8%-436.8%+446.6%
10Y-6.5%-599.3%+592.8%
1.1.2. Return on Assets

Shows how efficient Pharming is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • -0.7% Return on Assets means that Pharming generated €-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharming Group NV:

  • The MRQ is -0.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.7%TTM-0.6%-0.1%
TTM-0.6%YOY1.0%-1.6%
TTM-0.6%5Y1.6%-2.2%
5Y1.6%10Y-0.5%+2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.7%-13.6%+12.9%
TTM-0.6%-12.9%+12.3%
YOY1.0%-11.9%+12.9%
5Y1.6%-14.2%+15.8%
10Y-0.5%-16.2%+15.7%
1.1.3. Return on Equity

Shows how efficient Pharming is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • -1.4% Return on Equity means Pharming generated €-0.01 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharming Group NV:

  • The MRQ is -1.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.4%TTM-1.3%-0.1%
TTM-1.3%YOY1.8%-3.1%
TTM-1.3%5Y3.9%-5.2%
5Y3.9%10Y-21.6%+25.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.4%-17.0%+15.6%
TTM-1.3%-16.1%+14.8%
YOY1.8%-15.4%+17.2%
5Y3.9%-20.0%+23.9%
10Y-21.6%-21.1%-0.5%

1.2. Operating Efficiency of Pharming Group NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharming is operating .

  • Measures how much profit Pharming makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharming Group NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-15.2%+15.2%
TTM-15.2%YOY3.3%-18.5%
TTM-15.2%5Y15.1%-30.3%
5Y15.1%10Y16.3%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM-15.2%-224.4%+209.2%
YOY3.3%-288.4%+291.7%
5Y15.1%-475.2%+490.3%
10Y16.3%-624.7%+641.0%
1.2.2. Operating Ratio

Measures how efficient Pharming is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.28 means that the operating costs are €1.28 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Pharming Group NV:

  • The MRQ is 1.279. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.200. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.279TTM1.200+0.079
TTM1.200YOY0.993+0.207
TTM1.2005Y0.949+0.251
5Y0.94910Y0.953-0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2792.997-1.718
TTM1.2003.247-2.047
YOY0.9933.766-2.773
5Y0.9495.675-4.726
10Y0.9537.857-6.904

1.3. Liquidity of Pharming Group NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharming is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.06 means the company has €4.06 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharming Group NV:

  • The MRQ is 4.057. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.286. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.057TTM4.286-0.228
TTM4.286YOY5.207-0.922
TTM4.2865Y3.998+0.288
5Y3.99810Y3.200+0.798
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0573.930+0.127
TTM4.2864.251+0.035
YOY5.2075.436-0.229
5Y3.9986.045-2.047
10Y3.2006.363-3.163
1.3.2. Quick Ratio

Measures if Pharming is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • A Quick Ratio of 2.40 means the company can pay off €2.40 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharming Group NV:

  • The MRQ is 2.400. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.541. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.400TTM1.541+0.859
TTM1.541YOY0.611+0.930
TTM1.5415Y0.741+0.799
5Y0.74110Y0.599+0.143
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4003.629-1.229
TTM1.5414.065-2.524
YOY0.6115.397-4.786
5Y0.7415.993-5.252
10Y0.5996.277-5.678

1.4. Solvency of Pharming Group NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharming assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharming to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.53 means that Pharming assets are financed with 52.7% credit (debt) and the remaining percentage (100% - 52.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharming Group NV:

  • The MRQ is 0.527. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.527. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.527TTM0.527+0.000
TTM0.527YOY0.499+0.029
TTM0.5275Y0.548-0.021
5Y0.54810Y0.633-0.085
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5270.332+0.195
TTM0.5270.334+0.193
YOY0.4990.268+0.231
5Y0.5480.366+0.182
10Y0.6330.390+0.243
1.4.2. Debt to Equity Ratio

Measures if Pharming is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharming to the Biotechnology industry mean.
  • A Debt to Equity ratio of 111.6% means that company has €1.12 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharming Group NV:

  • The MRQ is 1.116. The company is able to pay all its debts with equity. +1
  • The TTM is 1.115. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.116TTM1.115+0.000
TTM1.115YOY0.997+0.119
TTM1.1155Y1.238-0.123
5Y1.23810Y3.186-1.948
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1160.381+0.735
TTM1.1150.390+0.725
YOY0.9970.334+0.663
5Y1.2380.434+0.804
10Y3.1860.466+2.720

2. Market Valuation of Pharming Group NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Pharming generates.

  • Above 15 is considered overpriced but always compare Pharming to the Biotechnology industry mean.
  • A PE ratio of -58.83 means the investor is paying €-58.83 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharming Group NV:

  • The EOD is -49.526. Based on the earnings, the company is expensive. -2
  • The MRQ is -58.827. Based on the earnings, the company is expensive. -2
  • The TTM is 31.881. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD-49.526MRQ-58.827+9.300
MRQ-58.827TTM31.881-90.708
TTM31.881YOY14.073+17.809
TTM31.8815Y-2.617+34.499
5Y-2.61710Y3.294-5.911
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-49.526-2.315-47.211
MRQ-58.827-2.560-56.267
TTM31.881-2.664+34.545
YOY14.073-4.122+18.195
5Y-2.617-6.258+3.641
10Y3.294-6.108+9.402
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharming Group NV:

  • The EOD is 13.753. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 16.336. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 12.961. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD13.753MRQ16.336-2.583
MRQ16.336TTM12.961+3.375
TTM12.961YOY173.504-160.543
TTM12.9615Y48.864-35.904
5Y48.86410Y33.700+15.165
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD13.753-3.067+16.820
MRQ16.336-3.251+19.587
TTM12.961-3.545+16.506
YOY173.504-5.595+179.099
5Y48.864-8.315+57.179
10Y33.700-8.708+42.408
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharming is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.36 means the investor is paying €3.36 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharming Group NV:

  • The EOD is 2.828. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.359. Based on the equity, the company is fair priced.
  • The TTM is 3.867. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.828MRQ3.359-0.531
MRQ3.359TTM3.867-0.508
TTM3.867YOY3.240+0.627
TTM3.8675Y5.107-1.240
5Y5.10710Y11.858-6.751
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8281.905+0.923
MRQ3.3592.111+1.248
TTM3.8672.095+1.772
YOY3.2402.836+0.404
5Y5.1073.443+1.664
10Y11.8583.794+8.064
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Pharming Group NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0070.004+93%0.012-42%0.011-35%0.011-33%
Book Value Per Share--0.3070.294+4%0.285+8%0.225+36%0.169+82%
Current Ratio--4.0574.286-5%5.207-22%3.998+1%3.200+27%
Debt To Asset Ratio--0.5270.527+0%0.499+6%0.548-4%0.633-17%
Debt To Equity Ratio--1.1161.115+0%0.997+12%1.238-10%3.186-65%
Dividend Per Share----0%-0%-0%-0%
Eps---0.004-0.004-14%0.005-190%0.006-171%0.001-462%
Free Cash Flow Per Share--0.016-0.007+143%0.007+111%0.007+120%0.007+120%
Free Cash Flow To Equity Per Share--0.014-0.007+150%0.006+152%0.009+57%0.009+57%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.349--------
Intrinsic Value_10Y_min---0.287--------
Intrinsic Value_1Y_max--0.003--------
Intrinsic Value_1Y_min--0.003--------
Intrinsic Value_3Y_max---0.020--------
Intrinsic Value_3Y_min---0.018--------
Intrinsic Value_5Y_max---0.078--------
Intrinsic Value_5Y_min---0.070--------
Market Cap572166490.112-21%691876513.533752057241.406-8%610069224.192+13%680380713.370+2%628396831.047+10%
Net Profit Margin---0.038-0.062+62%0.072-153%0.098-139%-0.065+68%
Operating Margin----0.1520%0.033-100%0.151-100%0.163-100%
Operating Ratio--1.2791.200+7%0.993+29%0.949+35%0.953+34%
Pb Ratio2.828-19%3.3593.867-13%3.240+4%5.107-34%11.858-72%
Pe Ratio-49.526+16%-58.82731.881-285%14.073-518%-2.617-96%3.294-1886%
Price Per Share0.868-19%1.0311.136-9%0.926+11%1.030+0%0.952+8%
Price To Free Cash Flow Ratio13.753-19%16.33612.961+26%173.504-91%48.864-67%33.700-52%
Price To Total Gains Ratio122.497-19%145.500200.816-28%392.543-63%248.703-41%157.931-8%
Quick Ratio--2.4001.541+56%0.611+293%0.741+224%0.599+301%
Return On Assets---0.007-0.006-9%0.010-171%0.016-142%-0.005-23%
Return On Equity---0.014-0.013-8%0.018-181%0.039-137%-0.216+1410%
Total Gains Per Share--0.0070.004+93%0.012-42%0.011-35%0.011-33%
Usd Book Value--218773813.044207102696.453+6%199639191.637+10%157985560.004+38%118278735.106+85%
Usd Book Value Change Per Share--0.0080.004+93%0.013-42%0.012-35%0.011-33%
Usd Book Value Per Share--0.3260.313+4%0.303+8%0.239+36%0.179+82%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.005-0.004-14%0.005-190%0.007-171%0.001-462%
Usd Free Cash Flow--11245630.569-4691345.884+142%5229828.195+115%4027117.705+179%2777322.555+305%
Usd Free Cash Flow Per Share--0.017-0.007+143%0.008+111%0.008+120%0.008+120%
Usd Free Cash Flow To Equity Per Share--0.015-0.008+150%0.006+152%0.010+57%0.010+57%
Usd Market Cap607698029.148-21%734842045.023798759996.098-8%647954523.014+13%722632355.671+2%667420274.255+10%
Usd Price Per Share0.922-19%1.0951.207-9%0.983+11%1.094+0%1.011+8%
Usd Profit---3122897.409-2636913.375-16%3418387.702-191%4292059.001-173%818731.724-481%
Usd Revenue--81214332.02261326985.342+32%51403811.329+58%48665201.296+67%41559289.905+95%
Usd Total Gains Per Share--0.0080.004+93%0.013-42%0.012-35%0.011-33%
 EOD+3 -5MRQTTM+18 -14YOY+15 -185Y+19 -1410Y+21 -12

3.2. Fundamental Score

Let's check the fundamental score of Pharming Group NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-49.526
Price to Book Ratio (EOD)Between0-12.828
Net Profit Margin (MRQ)Greater than0-0.038
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.400
Current Ratio (MRQ)Greater than14.057
Debt to Asset Ratio (MRQ)Less than10.527
Debt to Equity Ratio (MRQ)Less than11.116
Return on Equity (MRQ)Greater than0.15-0.014
Return on Assets (MRQ)Greater than0.05-0.007
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Pharming Group NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.587
Ma 20Greater thanMa 500.999
Ma 50Greater thanMa 1001.029
Ma 100Greater thanMa 2001.063
OpenGreater thanClose0.957
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Selling General Administrative  43,831-8,91234,9187,34442,262-8,36033,902-62,603-28,701



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets462,854
Total Liabilities244,073
Total Stockholder Equity218,781
 As reported
Total Liabilities 244,073
Total Stockholder Equity+ 218,781
Total Assets = 462,854

Assets

Total Assets462,854
Total Current Assets316,342
Long-term Assets146,512
Total Current Assets
Cash And Cash Equivalents 61,741
Short-term Investments 151,683
Net Receivables 35,408
Inventory 56,760
Total Current Assets  (as reported)316,342
Total Current Assets  (calculated)305,592
+/- 10,750
Long-term Assets
Property Plant Equipment 33,466
Long Term Investments 10,398
Intangible Assets 71,267
Long-term Assets Other 1,528
Long-term Assets  (as reported)146,512
Long-term Assets  (calculated)116,659
+/- 29,853

Liabilities & Shareholders' Equity

Total Current Liabilities77,968
Long-term Liabilities166,105
Total Stockholder Equity218,781
Total Current Liabilities
Short Long Term Debt 1,824
Accounts payable 16,022
Total Current Liabilities  (as reported)77,968
Total Current Liabilities  (calculated)17,846
+/- 60,122
Long-term Liabilities
Long term Debt 136,598
Capital Lease Obligations Min Short Term Debt33,123
Long-term Liabilities  (as reported)166,105
Long-term Liabilities  (calculated)169,721
+/- 3,616
Total Stockholder Equity
Total Stockholder Equity (as reported)218,781
Total Stockholder Equity (calculated)0
+/- 218,781
Other
Capital Stock7,669
Common Stock Shares Outstanding 671,073
Net Debt 76,681
Net Invested Capital 357,203
Net Working Capital 238,374
Property Plant and Equipment Gross 60,397



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
126,783
131,438
126,966
139,956
166,190
170,681
181,367
192,717
214,569
199,560
205,795
220,814
228,210
303,934
317,112
319,348
340,758
348,519
346,231
345,637
350,552
392,798
393,898
382,323
425,797
422,996
429,805
436,467
462,854
462,854436,467429,805422,996425,797382,323393,898392,798350,552345,637346,231348,519340,758319,348317,112303,934228,210220,814205,795199,560214,569192,717181,367170,681166,190139,956126,966131,438126,783
   > Total Current Assets 
62,190
66,105
61,115
73,658
88,251
94,437
105,476
115,546
115,440
101,689
101,215
101,788
106,503
178,909
195,391
197,623
214,343
223,343
211,137
208,804
249,444
250,948
256,980
252,048
277,500
266,056
278,573
291,737
316,342
316,342291,737278,573266,056277,500252,048256,980250,948249,444208,804211,137223,343214,343197,623195,391178,909106,503101,788101,215101,689115,440115,546105,47694,43788,25173,65861,11566,10562,190
       Cash And Cash Equivalents 
31,889
27,358
24,997
38,389
58,657
58,456
65,539
71,025
80,311
65,264
63,886
62,967
66,299
133,834
152,782
154,795
167,068
175,941
158,304
158,037
169,335
189,674
189,964
188,703
207,342
184,780
192,373
54,653
61,741
61,74154,653192,373184,780207,342188,703189,964189,674169,335158,037158,304175,941167,068154,795152,782133,83466,29962,96763,88665,26480,31171,02565,53958,45658,65738,38924,99727,35831,889
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
142,912
151,683
151,683142,912000000000000000000000000000
       Net Receivables 
11,386
19,846
18,645
17,274
10,183
14,370
16,775
23,570
16,001
22,783
24,624
26,985
23,458
30,564
26,386
26,446
25,965
28,050
31,569
28,285
27,591
31,445
32,878
28,828
27,619
32,931
33,158
40,521
35,408
35,40840,52133,15832,93127,61928,82832,87831,44527,59128,28531,56928,05025,96526,44626,38630,56423,45826,98524,62422,78316,00123,57016,77514,37010,18317,27418,64519,84611,386
       Inventory 
17,941
18,901
17,473
17,995
18,334
21,611
23,162
20,951
17,315
13,642
12,705
11,836
14,467
14,511
16,223
16,382
17,229
18,533
20,434
21,636
27,310
29,607
33,929
33,506
42,326
48,127
53,042
53,439
56,760
56,76053,43953,04248,12742,32633,50633,92929,60727,31021,63620,43418,53317,22916,38216,22314,51114,46711,83612,70513,64217,31520,95123,16221,61118,33417,99517,47318,90117,941
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
97,871
104,580
119,026
121,707
125,025
121,721
121,725
126,415
125,176
135,094
136,833
130,467
141,850
136,918
130,275
148,297
156,940
151,232
144,730
146,512
146,512144,730151,232156,940148,297130,275136,918141,850130,467136,833135,094125,176126,415121,725121,721125,025121,707119,026104,58097,871000000000
       Property Plant Equipment 
6,043
6,442
7,104
7,815
8,234
7,970
8,291
8,298
8,402
12,167
15,022
14,762
14,532
14,270
14,032
16,512
17,632
18,665
31,635
32,669
33,165
31,897
29,958
27,782
39,145
40,772
39,346
37,482
33,466
33,46637,48239,34640,77239,14527,78229,95831,89733,16532,66931,63518,66517,63216,51214,03214,27014,53214,76215,02212,1678,4028,2988,2917,9708,2347,8157,1046,4426,043
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
5,377
5,517
5,307
5,515
5,616
5,682
5,796
5,722
6,104
8,630
8,787
7,403
11,631
10,776
9,731
9,767
9,650
9,239
10,398
10,3989,2399,6509,7679,73110,77611,6317,4038,7878,6306,1045,7225,7965,6825,6165,5155,3075,5175,3770000000000
       Intangible Assets 
55,889
56,148
55,855
56,735
53,043
56,272
55,843
56,322
50,198
52,062
51,516
67,806
70,809
0
0
0
76,615
0
0
0
74,044
0
0
0
75,121
0
0
0
71,267
71,26700075,12100074,04400076,61500070,80967,80651,51652,06250,19856,32255,84356,27253,04356,73555,85556,14855,889
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
97,871
104,580
119,026
121,707
125,025
2,272
1,256
415
735
415
121
-439
797
746
197
1,099
1,212
1,722
1,464
1,528
1,5281,4641,7221,2121,099197746797-4391214157354151,2562,272125,025121,707119,026104,58097,871000000000
> Total Liabilities 
99,316
102,498
120,202
133,744
147,388
139,074
140,702
144,544
152,818
130,493
128,305
130,339
123,531
188,314
189,543
183,095
191,381
189,833
179,715
178,786
180,341
198,777
194,228
182,069
221,159
223,653
229,433
226,525
244,073
244,073226,525229,433223,653221,159182,069194,228198,777180,341178,786179,715189,833191,381183,095189,543188,314123,531130,339128,305130,493152,818144,544140,702139,074147,388133,744120,202102,49899,316
   > Total Current Liabilities 
51,378
61,591
34,461
56,132
58,528
59,120
64,373
86,287
82,599
62,269
65,973
90,103
101,886
44,399
43,890
36,504
62,579
62,873
40,199
40,277
46,771
45,151
49,194
46,694
59,698
59,003
64,952
68,058
77,968
77,96868,05864,95259,00359,69846,69449,19445,15146,77140,27740,19962,87362,57936,50443,89044,399101,88690,10365,97362,26982,59986,28764,37359,12058,52856,13234,46161,59151,378
       Short-term Debt 
67,393
65,590
90,494
16,908
21,962
27,945
35,174
35,924
35,235
34,963
33,607
34,432
45,590
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000045,59034,43233,60734,96335,23535,92435,17427,94521,96216,90890,49465,59067,393
       Short Long Term Debt 
67,393
65,590
90,494
16,908
21,962
27,945
35,174
35,924
35,235
34,963
33,607
34,432
45,590
0
0
0
1,661
2,607
1,657
1,657
1,657
1,844
1,728
1,627
1,768
1,805
1,797
1,748
1,824
1,8241,7481,7971,8051,7681,6271,7281,8441,6571,6571,6572,6071,66100045,59034,43233,60734,96335,23535,92435,17427,94521,96216,90890,49465,59067,393
       Accounts payable 
5,652
16,882
15,002
17,031
9,430
28,968
26,754
31,167
6,642
26,096
29,438
34,266
5,351
42,607
42,158
33,899
10,969
37,195
36,253
36,337
7,599
40,827
45,074
42,744
54,465
53,254
59,299
62,540
16,022
16,02262,54059,29953,25454,46542,74445,07440,8277,59936,33736,25337,19510,96933,89942,15842,6075,35134,26629,43826,0966,64231,16726,75428,9689,43017,03115,00216,8825,652
       Other Current Liabilities 
18,585
13,284
8,165
21,927
26,122
1,927
2,182
18,933
39,741
947
927
19,307
48,999
148
185
138
21,149
21,447
60
46
1,539
0
0
0
0
0
0
0
0
000000001,539466021,44721,14913818514848,99919,30792794739,74118,9332,1821,92726,12221,9278,16513,28418,585
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
68,224
62,332
40,236
21,645
143,916
145,653
146,591
128,802
126,960
139,516
138,509
139,076
153,626
145,034
135,375
161,461
164,650
164,481
158,467
166,105
166,105158,467164,481164,650161,461135,375145,034153,626139,076138,509139,516126,960128,802146,591145,653143,91621,64540,23662,33268,224000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
4,556
6,746
6,453
6,309
5,984
5,680
8,293
8,300
8,218
19,319
18,894
18,419
20,380
19,039
17,550
33,308
35,018
34,154
32,504
33,123
33,12332,50434,15435,01833,30817,55019,03920,38018,41918,89419,3198,2188,3008,2935,6805,9846,3096,4536,7464,556000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
1
18,298
18,298
173
161
159
333
146
162
152
143
0
0
0
0
0
0000014315216214633315916117318,29818,29810000000000000
       Deferred Long Term Liability 
791
0
0
0
3,588
0
0
0
2,237
0
0
0
4,304
0
0
0
4,443
0
0
0
266
0
0
0
0
0
0
0
0
000000002660004,4430004,3040002,2370003,588000791
> Total Stockholder Equity
27,467
28,940
6,764
6,212
18,802
31,607
40,665
48,173
61,751
69,067
77,490
90,475
104,679
115,620
127,569
136,253
149,377
158,686
166,516
166,851
170,211
194,021
199,670
200,254
204,638
199,343
200,372
209,942
218,781
218,781209,942200,372199,343204,638200,254199,670194,021170,211166,851166,516158,686149,377136,253127,569115,620104,67990,47577,49069,06761,75148,17340,66531,60718,8026,2126,76428,94027,467
   Common Stock
4,556
4,789
4,839
5,201
5,790
6,017
6,104
6,172
6,215
6,222
6,257
6,293
6,313
6,350
6,377
6,381
6,388
6,127
6,096
6,258
7,429
7,468
7,469
7,482
7,509
7,518
7,540
0
0
007,5407,5187,5097,4827,4697,4687,4296,2586,0966,1276,3886,3816,3776,3506,3136,2936,2576,2226,2156,1726,1046,0175,7905,2014,8394,7894,556
   Retained Earnings Total Equity00000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 00000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue245,316
Cost of Revenue-25,212
Gross Profit220,104220,104
 
Operating Income (+$)
Gross Profit220,104
Operating Expense-267,319
Operating Income-22,003-47,215
 
Operating Expense (+$)
Research Development68,914
Selling General Administrative87,501
Selling And Marketing Expenses-
Operating Expense267,319156,415
 
Net Interest Income (+$)
Interest Income3,663
Interest Expense-5,964
Other Finance Cost-134
Net Interest Income-2,435
 
Pretax Income (+$)
Operating Income-22,003
Net Interest Income-2,435
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-12,012-34,429
EBIT - interestExpense = -5,964
-10,548
-4,584
Interest Expense5,964
Earnings Before Interest and Taxes (EBIT)--6,048
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-12,012
Tax Provision--1,464
Net Income From Continuing Ops-10,548-10,548
Net Income-10,548
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net12,4262,435
 

Technical Analysis of Pharming
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharming. The general trend of Pharming is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharming's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharming Group NV.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.8945 < 0.9315 < 0.953.

The bearish price targets are: 0.8155 > 0.731 > 0.66.

Tweet this
Pharming Group NV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharming Group NV. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharming Group NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharming Group NV. The current macd is -0.02724009.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharming price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pharming. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pharming price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Pharming Group NV Daily Moving Average Convergence/Divergence (MACD) ChartPharming Group NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharming Group NV. The current adx is 36.08.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Pharming shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Pharming Group NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharming Group NV. The current sar is 1.0344079.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pharming Group NV Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharming Group NV. The current rsi is 21.59. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Pharming Group NV Daily Relative Strength Index (RSI) ChartPharming Group NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharming Group NV. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharming price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Pharming Group NV Daily Stochastic Oscillator ChartPharming Group NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharming Group NV. The current cci is -307.61836097.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Pharming Group NV Daily Commodity Channel Index (CCI) ChartPharming Group NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharming Group NV. The current cmo is -70.40098256.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pharming Group NV Daily Chande Momentum Oscillator (CMO) ChartPharming Group NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharming Group NV. The current willr is -95.78313253.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Pharming Group NV Daily Williams %R ChartPharming Group NV Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pharming Group NV.

Pharming Group NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharming Group NV. The current atr is 0.0308881.

Pharming Group NV Daily Average True Range (ATR) ChartPharming Group NV Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharming Group NV. The current obv is 215,174,280.

Pharming Group NV Daily On-Balance Volume (OBV) ChartPharming Group NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharming Group NV. The current mfi is 25.50.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Pharming Group NV Daily Money Flow Index (MFI) ChartPharming Group NV Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharming Group NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-04MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Pharming Group NV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharming Group NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.587
Ma 20Greater thanMa 500.999
Ma 50Greater thanMa 1001.029
Ma 100Greater thanMa 2001.063
OpenGreater thanClose0.957
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pharming with someone you think should read this too:
  • Are you bullish or bearish on Pharming? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharming? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharming Group NV

I send you an email if I find something interesting about Pharming Group NV.


Comments

How you think about this?

Leave a comment

Stay informed about Pharming Group NV.

Receive notifications about Pharming Group NV in your mailbox!